All posts by medical

This ‘Grey’s Anatomy’ Alum is One of the Most-Hated Actresses of All Time – Showbiz Cheat Sheet

The cast of Greys Anatomy has evolved on a large scale over the last 16 years with many being written off in controversial ways. While Ellen Pompeos Meredith Grey and a few other cast members have stuck around, no one will ever forget the debacle Katherine Heigl created.

Most fans remember when she was removed from the show due to her own heated comments. Part of that is still filled with debate on who was really right about the show.

Since those days, Heigl has had some problems keeping her movie and TV career consistent. While shes still working, shes lost some of the popularity she once had, perhaps for a variety of reasons.

According to some sources, its mostly due to issues she exhibits behind-the-scenes in her career.

Her troubles with Greys Anatomy and Shonda Rhimes began when Heigl began complaining about the quality of her role as Dr. Izzie Stevens. She claimed the writers were making her character do things she didnt think Izzie would do.

Perhaps she was half-right based on some of the silly romances the character was having. However, the final clincher was when Heigl took her name out of contention for an Emmy in 2008. This perturbed the writers and Rhimes herself since they thought Heigl was disrespecting cast and crew.

As many know now, when Rhimes doesnt see eye-to-eye with a cast member, she usually writes them out in less than glamorous ways. Heigl was let go from the show and Dr. Izzie Stevens was never seen again after the sixth season.

Rumors keep popping up Heigl will show up again if Greys Anatomy ever ends. Dont count on it since theres reportedly a lot of issues people in the movie/TV industry still have with her as an actress and person.

Whether you can consider certain online sources legit or not is up to the reader to decide. One South African source called News24 published a piece in 2014 detailing ten reasons Heigl was one of the most hated in the entertainment world.

The top ten list was long with myriad details of her supposedly doing nearly unbearable things on the set of shows and films. Its said she has a long track record of questioning scripts and her wardrobe, not including demanding bigger paychecks than her fellow actors.

Then they mention her mom whos also her manager. From all reports, her mom is overly protective and vindictive, making her resemble a cliched stage mother. Both are said to have potty mouths while saying negative things about their colleagues behind their backs.

Whether all of this can be corroborated without evidence is another thing. When it comes to women working in the industry, having them forced to do certain things means having to speak up and sometimes be considered a diva when theyre just protecting themselves.

One thing brought up again in the above top ten list is when Heigl decried sexism in the film Knocked Up in 2008. This was her first major movie role, but she wasnt afraid to speak up about something arguably true.

For some, this was just looked at as being disloyal to cast and crew, which has its own point. Heigl has undoubtedly felt she had to be this way at times to get ahead and survive in a tough industry.

Yet, theres always a happy medium on how to go about it so it doesnt become misinterpreted as being a diva. At least the #MeToo movement has allowed other actresses to speak up about things they shouldnt have to put up with on a production set.

In the case of Heigl, she still has enough supporting her to keep working since she does have a web series called Firefly Lane arriving soon, not including finishing up a run on Suits. As much as Heigl might be disliked by some, theres always going to be another half who see eye to eye with her opinions.

More here:
This 'Grey's Anatomy' Alum is One of the Most-Hated Actresses of All Time - Showbiz Cheat Sheet

WATCH: Delhi Riot Reportage Anatomy: 10 big challenges of covering the mayhem | The Last Word – Times Now

EP470 - WATCH: Delhi Riot Reportage Anatomy: 10 big challenges of covering the mayhem | The Last Word26 FEBRUARY 2020 | MIRROR NOW TV | 57 MIN 32 SEC

On The Last Word, The anatomy of covering a riot. 10 big challenges of covering Delhi mayhem. Today's show is about the invisible heroes of any news channel, reporters and video journalists, who have been working in the most challenging times.

CHALLENGE: How reporters' & Video Journalists identity turns into a big risk.

CHALLENGE: Deciding where to park, leave the getaway vehicle, essentials & equipments.

CHALLENGE: Why it's tough to distinguish facts from fake news and How knowledge of identifying sounds is a lifesaver.

Locals from Khajuri Khas in Delhi vacate their houses. They've lost all their properties, vehicles and documents.

Watch for more details.

View original post here:
WATCH: Delhi Riot Reportage Anatomy: 10 big challenges of covering the mayhem | The Last Word - Times Now

Effectiveness and safety assessment of drospirenone/ethinyl estradiol tablet in treatment of PCOS patients: a single center, prospective,…

Study population

This single center, prospective observational study was conducted from August 2017 to December 2018. Among the 173 patients with PCOS who were enrolled from the Department of Gynecology, Guangdong Maternal and Child Health Hospital, only 140 patients completed the study treatment protocol. The study was approved by Institutional ethical committee of Guangdong Maternal and Child Health Hospital. The study was conducted in accordance with the Good Clinical Practice guidelines and Declaration of Helsinki.

Considering that the prevalence of PCOS is 610%, a minimum sample size of 122 was required at a 1% level of significance with a power of 90%. However in order to account for any attrition, a total of 140 patients were enrolled.

Patients who qualified for PCOS as per the European Society of Human Reproduction and Embryology and the American Society of Reproductive Medicine at the Rotterdam Conference in 2003 [4] were included. Additionally, patients with no contraindication to oral contraceptives, who were confident of being compliant to the drug and provided informed consent were also included. On the other hand, patients with any contraindications to oral contraceptives; desirous of conception within 6months of inclusion in the study; diagnosed with concomitant hypothyroidism, hyperprolactinemia, diabetes mellitus, renal, or adrenal insufficiency; history of drug use for PCOS before inclusion in the study, and history of smoking and drug abuse were excluded from the study.

The patients at clinicians discretion received DRSP/EE tablets (Yousiyue, Bayer Medical and Health Company, Import Drug Registration No. H20140972). Each strip contained 28 tablets; 24 active tablets and 4 placebo tablets. Every active tablet contained 20g of EE and 3mg of DRSP. Patients were instructed to take oral DRSP/EE tablets (once daily before bedtime) on the 2nd day of menstruation or on the second day of withdrawal bleeding, for 28 consecutive days for 1cycle. There were 3 consecutive treatment cycles and patients were followed up for 3months of treatment.

Although, till date no established evidence exists whether a short- or a long-term usage of COC is beneficial in terms of efficacy and safety benefits, it is considered best to review the effects after 3months. Most studies show that unscheduled bleeding is more likely in the first cycle, and some show an improvement over the first 3months, with the incidence of unscheduled bleeding remaining constant from 4 to 12months for OC in Chinese women [15]. Thus, it is recommended that women experiencing unscheduled bleeding continue their method for at least 3months before seeking advice. With this background, we set up a 3month trial period to assess the effect of 3mg DRSP/20g EE in PCOS patients for 3months.

Baseline data were collected from the patients including demographic details such as age and presenting complaints (menstrual history, drug history, etc.). Patients weight was recorded using a digital scale, height using a stadiometer (Guangzhou Quality and Technical Supervision Bureau Guangzhou Institute of Metrology and Measurement Technology Measuring Instruments No. 794067), waist-hip ratio (WHR) was measured using a standard measuring tape and body mass index (BMI) was calculated. Additionally, hormonal profile [leutinizing hormone (LH), follicular stimulating hormone (FSH), testosterone (T), free androgen index (FAI), androgen] and biochemical parameters[fasting plasma glucose (FPG), 2-hourblood glucose (oral glucose tolerance test using 83g glucose in 250300ml water), fasting insulin (FINS), total cholesterol (TC), triglycerides (TG), high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C)] were measured using fasting blood samples followed by an overnight fast. Variation in Homeostasis model assessment of insulin resistance (HOMA-IR) was also assessed at end of treatment regimen [16].Ovarian volume was measured by gynecological ultrasonography (Samsung, specification model: H60, host serial number: S10LM3HHB00009A). After 3months of medication, the above indicators were reviewed and compared. Similarly, bleeding pattern during medication and presence of adverse reactions (ADRs) were also recorded.

Menstrual bleeding volume was categorized into drip, small, normal and large amount of bleeding. Drip bleeding was defined when the need of sanitary napkin was not required. When the volume was lesser than the normal menstrual bleeding, it was considered as small amount of bleeding and normal was when the bleeding volume was similar to normal menstrual cycle. Large amount of bleeding was defined as volume more than the regular cycle. As recommended by WHO, the 90days was considered as a reference period to calculate the amount / number of days and times of drip bleeding.

All statistical analyses were performed using SPSS16.0 software. Missing data were excluded from the analysis. Continuous data were expressed as meanstandard deviation and categorical data were expressed as percentages (%).25th, 50th, and 75th percentiles were also calculated. If the normal distribution was not met for Students t-test, the signed rank sum test of the paired design data was used and the difference was considered statistically significant at p<0.05.

More here:
Effectiveness and safety assessment of drospirenone/ethinyl estradiol tablet in treatment of PCOS patients: a single center, prospective,...

Rtdeen Farms 22nd Annual Genetics with a Vision Production Sale – Tri-State Livestock News

TSLN Rep: Dennis Ginkens

Date of Sale: Feb. 8, 2020

Location: at the Farm, Clearbrook, MN

Auctioneer: Tracy Harl

Averages:

75 Bulls $3,870

30 Bred Females $2,523

12 Open heifers $1,263

Lot 61 at $10,000-Black, PB SM Bull, RFS Grizzly G65, s. by Ellingson Load Up, sold to Steve Fallgatter, ND

Lot 14 at $8,000Black, blood SM Bull, RFS Gage G15, s. by WS Proclamation, sold to Kellers Broken Heart Ranch, ND

Lot 13 at $6,000Black, PB SM Bull, RFS Gentry G8, s. by WS Proclamation, sold to Emmons Ranch, MT

High selling Bred Female & Heifer

Lot 82 at $4,000 Black, PB Bred, RFS Miss Francie F57s. by Ellingson Load up, bred to Direct Impact, sold to Mark Nesemeier, ND.

Lot 120 at $1,700 Red, PB Open, RFS Miss Georgia, G160 s. by KBHR Kingsman, sold to Brant Farms, MN

Original post:
Rtdeen Farms 22nd Annual Genetics with a Vision Production Sale - Tri-State Livestock News

PECASE Honoree Sohini Ramachandran Studies the Genetic Foundations of Traits in Diverse Populations – Newswise

Newswise Recent advances in computing enable researchers to explore the life sciences in ways that would have been impossible a few decades ago. One new tool is the ability to sequence genomes, revealing peoples full DNA blueprints. The collection of more and more genetic data allows researchers to compare the DNA of many people and observe variations, including those shared by people with a common ancestry.

Sohini Ramachandran, Ph.D., is director of the Center for Computational Molecular Biology and associate professor of biology and computer science at Brown University in Providence, Rhode Island. She is also a recent recipient of the Presidential Early Career Award for Scientists and Engineers (PECASE). Dr. Ramachandran researches the causes and consequences of human genetic variations using computer models. Starting with genomic data from living people, her lab applies statistical methods, mathematical modeling, and computer simulations to discover how human populations moved and changed genetically over time.

Sohini Ramachandran, Brown University. Credit: Danish Saroee/Swedish Collegium for Advanced Study.

Dr. Ramachandran and her team focus on further uncovering how the genetic architecture, or composition of traits, varies among people with different ancestries. Variations in the genetic composition of disease-causing genes can make individuals respond differently to the same therapy, and understanding these variations could help doctors recommend the best treatment for each patient.

Many of the large genome-wide association studies that have looked for the basis of traits or diseases have been in populations of European ancestry, with the assumption that their genetic architecture is the same across populations. However, this isnt necessarily the case. Most diseases are caused by the interaction of many genetic variants. As a result, people who have different ancestries and the same disease may share some disease-causing variants but have population-specific variants that also play a role in the disease.

Dr. Ramachandran is excited to bring her knowledge of human evolutionary histories into studying genetic variation to better understand and potentially treat diseases and to identify adaptive mutations. She says evolutionary histories can help researchers make sense of data from the genome-wide association studies used to investigate diseases, understand why results from these studies are often difficult to replicate, and determine if results apply only to certain populations. The genome-wide association studies have a lot of downstream effects because some of the results from these studies are affecting decisions that are being made in clinics, and its not clear if those results are relevant to everyone, she says.

For Dr. Ramachandran, receiving a PECASE highlights the importance of statistical and computational work in human genetics and disease and reinforces the value of including evolutionary biology in modern medical practices.

Dr. Ramachandrans research is supported in by part NIGMS grants R01GM118652 and P20GM109035.

Read the original:
PECASE Honoree Sohini Ramachandran Studies the Genetic Foundations of Traits in Diverse Populations - Newswise

CIBC Innovation Banking Provides InformedDNA With US$10 Million Growth Financing – Yahoo Finance

CIBC Innovation Banking is pleased to announce a US$10 million growth capital financing for InformedDNA.

Founded in 2005, InformedDNA was built with the vision to provide genetic testing services to patients and health insurers. The company optimizes genetic-related healthcare spending and patient care by improving access to clinical and scientific genomics expertise. It is the nations largest independent provider of genetic specialists enabled by a comprehensive evidence-based knowledge library for genetic tests and hereditary conditions.

InformedDNA recently announced a strategic growth investment with private equity funds TT Capital Partners, NovaQuest Capital Management, and Frist Cressey Ventures. The company will use the capital to continue scaling its technology and expand its staff of genetic counselors.

"InformedDNA has a deep understanding of the genetic testing space and uses this knowledge to help both patients and insurance companies improve outcomes," said Jeff Chapman, a Managing Director in CIBC Innovation Bankings Menlo Park office.

"CIBC Innovation Banking understands the capital needs of our business and is willing to provide a flexible debt solution so we can continue to execute on our business strategy," added David Nixon, CEO of InformedDNA.

About CIBC Innovation Banking

CIBC Innovation Banking delivers strategic advice, cash management and funding to North American innovation companies at each stage of their business cycle, from start up to IPO and beyond. With offices in Atlanta, Austin, Chicago, Denver, Menlo Park, Montreal, Reston, Toronto and Vancouver, the team has extensive experience and a strong, collaborative approach that extends across CIBCs commercial banking and capital markets businesses in the U.S. and Canada.

About InformedDNA

InformedDNA is the authority on the appropriate use of genetic testing. It leverages the expertise of the largest full-time staff of independent, board-certified genetics specialists in the U.S. to help ensure health plans, hospitals, employers, clinicians and patients all have access to the highest quality genetic services. Key offerings include clinical genetic counseling, genetic testing utilization management, genetic testing payment integrity, and expert genetics clinical trial support. For more information: http://www.InformedDNA.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20200227005493/en/

Contacts

Kathryn Lawler, 416-242-1943kathryn.lawler@cibc.com

Continued here:
CIBC Innovation Banking Provides InformedDNA With US$10 Million Growth Financing - Yahoo Finance

World Flow Cytometry Industry Outlook, 2020-2027 – Featuring Company Profiles for Agilent Technologies, Thermo Fisher Scientific, BD & Co,…

DUBLIN, Feb. 26, 2020 /PRNewswire/ -- The "Flow Cytometry Market by Product and Solution (Consumables, Instrument, Software, Service), Technology (Cell-based, Bead-based), Application (Cancer, Immunology, Hematology), and End-user (Pharmaceutical, Biotech, Academia) - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global flow cytometry market is expected to grow at a CAGR of 8.2% from 2019 to 2027 to reach $6.36 billion by 2027.

The growth in the overall flow cytometry market is mainly attributed to rising global incidence and prevalence of chronic diseases, increasing adoption of flow cytometry techniques in research and academia, and growing initiatives in the field of immunology and immuno-oncology researches. In addition, evolving pipeline for stem cell research and adoption of recombinant DNA technology for antibody production will further provide significant opportunities for the various stakeholders in this market.

The overall flow cytometry market is mainly segmented by product and solution (instruments, software, accessories, services), technology (cell-based flow cytometry, bead-based flow cytometry), application (research, clinical, and industrial), end user (research and academic institutes, diagnostic laboratories, pharmaceutical & biotechnology companies), and geography.

On the basis of technology, bead-based technology segment is expected to grow at the highest CAGR during the forecast period. Procedural advantages offered by this technology over other cell-based technologies (such as ELISA and western blot), including its capacity to detect multiple analytes, high reproducibility, stability, and speed are expected to propel its growth.

On the basis of product and solution, the consumables and reagents segment accounted for the largest share of the overall flow cytometry market in 2019. Frequent utilization of application-specific reagents and assays by the end users is supporting the growth of this segment.

On the basis of application area, drug discovery segment held the largest share of the overall flow cytometry market in 2019. A wide variety of flow cytometry methods with the implementation of multi-parameter intracellular flow cytometric analysis have been employed at different stages of drug discovery and development. The growing demand for such advanced technologies used during drug discovery processes to simplify complicated cell analysis procedures is expected to drive the growth of this segment.

Based on end user, the pharmaceutical and biotechnology companies segment accounted for the largest share of this market in 2019. Increasing chronic cases leading to the development of new drugs and rise in R&D expenditure by companies is contributing to the growth of this segment.

An in-depth analysis of the geographical scenario of the flow cytometry market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. North America commanded the largest share of the global flow cytometry market in 2019, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

The key players operating in the global flow cytometry market are Agilent Technologies, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Apogee Flow Systems Ltd. (U.K.), Sysmex Partec GmbH (Germany), Luminex Corporation (U.S.), Miltenyi Biotec GmbH (Germany), Bio-Rad Laboratories, Inc. (U.S.), bioMerieux S.A. (France), Cytonome/ST LLC (U.S.), Beckman Coulter, Inc. (U.S.), and Becton, Dickinson and Company (U.S.) among others.

Story continues

Key Topics Covered

1. Introduction1.1. Market Definition1.2. Market Ecosystem1.3. Currency1.4. Key Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Dynamics4.1. Introduction4.2. Drivers4.2.1. Rising Incidence and Prevalence of Chronic Diseases4.2.2. Growing Initiatives in the Field of Immunology and Immuno-Oncology Researches4.2.3. Adoption of Flow Cytometry Techniques in Research and Academia4.2.4. Flow Cytometry Based Technological Advancements4.3. Restraint4.3.1. Lack of Skilled Professionals4.4. Opportunities4.4.1. Growing Research Activities in Stem Cells4.4.2. Emerging Markets4.4.3. Adoption of Recombinant DNA Technology for Antibody Production4.5. Challenges4.5.1. Inadequate Research infrastructure across Emerging Countries4.5.2. Complexities Related to Reagent Development

5. Flow Cytometry Market, by Product & Solution5.1. Introduction5.2. Consumables and Reagents5.3. Instruments5.3.1. Cell Analyzers5.3.2. Cell Sorters5.4. Software5.5. Accessories5.6. Services

6. Flow Cytometry Market, by Technology6.1. Introduction6.2. Cell-Based Flow Cytometry6.3. Bead-Based Flow Cytometry

7. Flow Cytometry Market, by Application7.1. Introduction7.2. Research Applications7.2.1. Drug Discovery7.2.2. Stem Cell Research7.2.3. Immunology7.2.4. Cell Sorting7.2.5. Apoptosis7.2.6. Other Research Applications7.3. Clinical Applications7.3.1. Cancer7.3.2. Organ Transplantation7.3.3. Immunodeficiency Diseases7.3.4. Hematology7.3.5. Other Clinical Applications7.4. Industrial Applications

8. Flow Cytometry Market, by End-user8.1. Introduction8.2. Pharmaceutical & Biotechnology Companies8.3. Diagnostic Laboratories8.4. Research & Academic institutes

9. Global Flow Cytometry Market, by Geography9.1. Introduction9.2. North America9.2.1. U.S.9.2.2. Canada9.3. Europe9.3.1. Germany9.3.2. France9.3.3. U.K.9.3.4. Italy9.3.5. Spain9.3.6. Rest of Europe9.4. Asia-Pacific9.4.1. Japan9.4.2. China9.4.3. India9.4.4. Rest of Asia-Pacific9.5. Latin America9.6. Middle East & Africa

10. Competitive Landscape10.1. Introduction10.2. Key Growth Strategies10.3. Competitive Benchmarking10.4. Market Share Analysis (2018)

11. Company Profiles(Business Overview, Financial Overview, Product Portfolio, Strategic Developments)11.1. Agilent Technologies Inc.11.2. Thermo Fisher Scientific Inc.11.3. Becton, Dickinson & Company11.4. bioMerieux S.A.11.5. Beckman Coulter Inc. (Subsidiary of Danaher Corporation)11.6. Bio-Rad Laboratories Inc.11.7. Luminex Corporation11.8. Cytonome/St, LLC11.9. Apogee Flow Systems Ltd.11.10. Sysmex Partec GmbH (Subsidiary of Sysmex Corporation)11.11. Miltenyi Biotec B.V. & Co. KG

For more information about this report visit https://www.researchandmarkets.com/r/1mj41m

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/world-flow-cytometry-industry-outlook-2020-2027---featuring-company-profiles-for-agilent-technologies-thermo-fisher-scientific-bd--co-biomerieux-beckman-coulter-bio-rad-labs-and-more-301011564.html

SOURCE Research and Markets

More:
World Flow Cytometry Industry Outlook, 2020-2027 - Featuring Company Profiles for Agilent Technologies, Thermo Fisher Scientific, BD & Co,...

Allergists Offer Advice to Parents of Kids With Food Allergies – The New York Times

The allergists also talked about creating thoughtful and balanced communication, having credible health information to share with children, and supporting a positive feedback loop between parents and children rather than one that builds anxiety. "Parents should be encouraged to transfer their knowledge to children, not all of their worries," one expert remarked.

"Psychosocial coping with food allergies can be understood and managed when clear communication is present between parents and children and between healthcare providers and patients," Gupta said. "It is a balance between lots of sound medical information and a good understanding of a child's risks and coping resources."

Coping is often impeded by misinformation about food allergies, the experts said, so it's important for parents to receive consistent messaging and counseling for the family, if necessary.

"You are taking care of the kids, but you are (also) managing the family unit, as you should be," one allergist said.

Brochures, apps, virtual groups and other educational materials can offer scientifically informed resources for parents and kids to manage food allergies. Gupta and colleagues are now collecting information in an online survey about the coping strategies and integrative medicine that parents and children have used.

"It's important for families to know that it's normal to be stressed about food allergy and feel overwhelmed, worried, sad or frustrated at times," said Linda Herbert, director of the Psychosocial Services Program for the Division of Allergy and Immunology at Children's National Hospital in Washington, D.C.

"But it's equally important to know that they can get help from a professional," Herbert, who wasn't involved in the study, told Reuters Health by email. "The mental health and allergy communities are paying more and more attention to the needs of food allergy families, and we are working hard to increase the number of mental health professionals who are equipped to do so."

SOURCE: https://bit.ly/2utQCOm Annals of Allergy, Asthma & Immunology, online February 25, 2020.

See original here:
Allergists Offer Advice to Parents of Kids With Food Allergies - The New York Times

Research Funding Available for Preeclampsia and Related Pregnancy Disorders – P&T Community

MELBOURNE, Fla., Feb. 26, 2020 /PRNewswire/ --The Preeclampsia Foundation announced that applications are now being accepted for its 2020 Vision Grant program.

The Preeclampsia Foundation will award up to two medical research Vision Grants to study preeclampsia and related hypertensive disorders of pregnancy, up to $20,000 USD each. The Foundation's Canadian affiliate, Preeclampsia Foundation Canada, will also award up to two Vision Grants up to $20,000 CAD each, to a Canadian researcher.

Vision Grants are intended to provide initial funding for novel, innovative research by promising young investigators that will advance progress towards detection, prevention, or treatment of preeclampsia, HELLP syndrome, and other hypertensive disorders of pregnancy. Post-doctoral, Clinical Fellows, or Early Stage Investigators only are eligible to apply. Projects with potential to alter clinical management and improve patient outcomes will receive priority, but any well-considered research proposal will be accepted for review.International applications are welcome; however,submissions must be in English.

Application deadline is May 8, 2020, with award notification in August 2020. Instructions can be found at http://www.preeclampsia.org/research/research-funding (US) or http://www.preeclampsiacanada.ca (Canada).

Since its inception, the Preeclampsia Foundation's Vision Grant annual program has invested more than $550,000 in novel research ranging from molecular biology and immunology to potential therapies, with the goal of supporting new, potentially groundbreaking concepts. These results have, in turn, generated additional funding from the National Institutes of Health, earned scientific presentations at major conferences, and inspired young investigators to challenge a medical conundrum that has baffled the medical community for more than 2,400 years.

"We look forward to receiving diverse, quality applications again this year," said Dr. Thomas Easterling, director of the Preeclampsia Foundation's Medical Advisory Board. "There has been significant progress toward understanding preeclampsia during the past two decades, but there's much more research that needs to be done. We're pleased to be able to fuel this work through our Vision Grants for young investigators."

"It's exciting to be part of research and innovation that will lead to improved maternal and infant health and someday a cure," said Violet Mateljan, President of the Preeclampsia Foundation Canada Board of Directors."Preeclampsia Foundation Canada is very proud to be able to support a junior researcher with a Vision Grant in Canada."

About the Preeclampsia Foundation Vision Grant Award program:Funds medical research pertaining to the pathophysiology, diagnosis, and treatment of hypertensive disorders of pregnancy.

About the Preeclampsia Foundation: The Preeclampsia Foundation is a U.S.-based 501(c)(3) non-profit organization established in 2000. It is dedicated to providing patient support and education, raising public awareness, catalyzing research, and improving healthcare practices, envisioning a world where preeclampsia and related hypertensive disorders of pregnancy no longer threaten the lives of mothers and babies.For more information, visit http://www.preeclampsia.org.

About Preeclampsia Foundation Canada: Preeclampsia Foundation Canada was incorporated under the Canada Not-for-profit Corporations Act in May 2015. As an affiliate of the U.S. based Preeclampsia Foundation, its mission is to raise awareness and advance education and research of hypertensive disorders of pregnancy. For more information, visit http://www.preeclampsiacanada.ca.

Contact: Valerie Holloway (321) 421-6957 234909@email4pr.com

View original content:http://www.prnewswire.com/news-releases/research-funding-available-for-preeclampsia-and-related-pregnancy-disorders-301011676.html

SOURCE Preeclampsia Foundation

View post:
Research Funding Available for Preeclampsia and Related Pregnancy Disorders - P&T Community

Roche To Top $66 Billion In Sales By 2020, Led By Neuroscience – Trefis

Roche Holdings(OTCMKTS:RHHBY) revenue grew at a CAGR of 5.3% from $52.5 billion in 2015 to $64.4 billion in 2019, and it is estimated to top $66 billion in 2020, led by its Neuroscience drugs. The companys oncology drugs will account for 45% of the companys total sales in 2020, but Neuroscience drugs are key to the near term revenue growth, in our view.Oncology drugs are expected to be the single-biggest revenue driver with $30.1 billion in revenues (45% of Total Revenues), which is 5.7x the size of its Neuroscience drugs revenue in 2020. Neuroscience drugs revenues, which includes Ocrevus and Modopar among other drugs, will be the fastest-growing segment adding $3.7 billion over 2017-2020 (32% of $11.6 billion in incremental revenues). Oncology drugs revenues, which includes Herceptin, Perjeta, Tecentriq, and Avastin among other drugs, will add about $3.4 billion over 2017-2020 (29% of the $11.6 billion in incremental revenue). Look at our interactive dashboard analysis on Roches Revenues for more details, parts of which are highlighted below.

Roches Revenue Has Been On A Rise Over The Last Few Years

Roche Has One of The Largest Oncology Drugs Portfolio, But It Is Expected To See A Decline Going Forward.

Ocrevus Has Been The Best Drug Launch Ever For Roche, Boosting Its Neuroscience Drugs Portfolio

Other Therapeutic Drugs Could Also See Growth In The Near Term

Among Other Segments, In-Vitro Diagnostics Could Continue To Grow At A Steady Pace, While Immunology, Ophthalmology, And Virology Drugs Could See A Decline

See allTrefis Price EstimatesandDownloadTrefis Datahere

Whats behind Trefis? See How Its Powering New Collaboration and What-Ifs ForCFOs and Finance Teams|Product, R&D, and Marketing Teams

Link:
Roche To Top $66 Billion In Sales By 2020, Led By Neuroscience - Trefis